Aptevo Therapeutics (NASDAQ:APVO) had its target price lifted by stock analysts at Piper Jaffray Companies from $4.00 to $4.50 in a report issued on Monday, The Fly reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 445.45% from the company’s previous close.

Several other research analysts have also commented on APVO. ValuEngine lowered shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Zacks Investment Research upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Thursday, March 14th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $7.88.

NASDAQ APVO traded down $0.01 during trading on Monday, hitting $0.83. The company had a trading volume of 778,028 shares, compared to its average volume of 1,160,525. The company has a current ratio of 2.76, a quick ratio of 2.66 and a debt-to-equity ratio of 0.63. Aptevo Therapeutics has a one year low of $0.78 and a one year high of $6.35. The firm has a market capitalization of $35.43 million, a PE ratio of -0.35 and a beta of 2.88.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.09). Aptevo Therapeutics had a negative return on equity of 108.06% and a negative net margin of 232.68%. On average, sell-side analysts predict that Aptevo Therapeutics will post -1.14 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in APVO. Deutsche Bank AG grew its position in shares of Aptevo Therapeutics by 251.7% in the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after buying an additional 236,300 shares during the period. Renaissance Technologies LLC grew its position in shares of Aptevo Therapeutics by 11.1% in the 3rd quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock worth $6,488,000 after buying an additional 127,700 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Aptevo Therapeutics by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock worth $7,242,000 after buying an additional 73,911 shares during the period. Clifford Swan Investment Counsel LLC purchased a new stake in shares of Aptevo Therapeutics in the 4th quarter worth about $35,000. Finally, Acadian Asset Management LLC grew its position in shares of Aptevo Therapeutics by 4.8% in the 4th quarter. Acadian Asset Management LLC now owns 462,824 shares of the biotechnology company’s stock worth $587,000 after buying an additional 21,059 shares during the period. 17.08% of the stock is currently owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Featured Story: How to invest in blue-chip stocks

The Fly

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.